A Pharmacogenomic Study of Candesartan in Heart Failure
NCT00400582
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Heart Failure
Interventions
DRUG:
Candesartan up to 32 mg daily
Sponsor
Montreal Heart Institute
Collaborators
[object Object]